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ABSTRACT The Tat-responsive region (TAR) sequence is
present at the 5' end of human imuodeficiency virus 1
mRNAs and as a cytoplasmic form of 58-66 nucleotldes. TAR
RNA blocks the activation and autophosphorylation of the
double-stranded RNA-activated protein kinase in vitro. We
show here that TAR RNA also prevents the double-stranded
RNA-mediated inhibition of talation in a cell-free system.
Mutagenic and structural analyses of TAR RNA indicate that
a stem of at least 14 base pairs is required for this activity,
whereas the loop and bulge required for transactivation by Tat
are dispensable. Truncation of the RNA to 68 nucleotides
results in the loss oftranslational rescue ability, s tg that
the short cytoplasmic TAR RNA produced by viral trascrip-
tion in vivo may not have the capability to suppress activation
of the kinase. However, because longer TAR rascripts stim-
ulate expression in a transient assay in vivo, the TAR structure
at the 5' end of viral mRNAs could still exert this fumction in
Cis.
Human immunodeficiency virus type 1 (HIV-1) encodes
several regulatory proteins essential for its replication (1, 2).
Tat is a powerful transactivator of viral gene expression that
acts through an RNA element, the Tat-responsive region
(TAR) located between nucleotides (nt) + 14 to +44, relative
to the transcriptional start site in the long terminal repeat.
TAR RNA forms a stable structure containing a stem, bulge,
and loop, in which the integrity ofthe bulge and adjacent stem
is important for interaction with the Tat protein. Tat interacts
directly with TAR RNA to stimulate viral gene expression at
the transcriptional level and possibly at posttranscriptional
levels (1, 2). TAR RNA is present at the 5' end of HIV-1
primary transcripts and mRNAs and as a cytoplasmic form of
58-66 nt (3, 4). The stability of this short form (3-8) suggests
that it may play a role in the viral life cycle, and its apparently
cytoplasmic location has prompted investigations of a trans-
lational function (9-14).
TAR RNA interacts with several cellular proteins, includ-
ing a protein kinase, the double-stranded (ds)RNA-activated
inhibitor of translation (DAI) (10-14). Synthesis of this
enzyme (also referred to as p68 kinase, dsI, and P1) is induced
by interferon, and it is important in the cellular defense
against viral infection (15). DAI occurs in an inactive state in
most mammalian cells and is activated during viral infection
by dsRNA-mediated autophosphorylation. The activated en-
zyme phosphorylates the a subunit of eukaryotic initiation
factor 2 (eIF-2) (16), which then traps another initiation
factor, the guanine nucleotide exchange factor (GEF or
eIF-2B). Protein synthesis is thereby blocked, and viral
propagation is impaired.
Several viruses have developed ways to combat the DAI-
mediated cellular defense mechanism (17). Particularly rele-
vant here are the adenovirus virus-associated (VA) RNAs
and Epstein-Barr virus-encoded RNAs (EBERS), small
highly structured RNAs that block the activation of DAI by
dsRNA (18). Similarly, the TAR RNA of HIV-1 can inhibit
the activation ofDAI by dsRNA in a kinase assay containing
purified enzyme and RNA (13). We have extended this
observation to more physiological systems, both in vivo and
in vitro. The rabbit reticulocyte lysate responds to a variety
of physiological stimuli that regulate translation and in many
ways affords a reliable representation of the in vivo situation
(19). TAR RNA blocks dsRNA-mediated inhibition of cell-
free translation, indicating that it inhibits activation of DAI
by dsRNA in this system. To determine the structural fea-
tures of the RNA that are important for its DAI inhibitory
property, we made mutations at different positions in the
TAR sequence. The mutant RNAs were examined structur-
ally and tested for their translational rescue ability in cell-free
translation. The results show that the stem of the molecule,
but not its Tat-binding elements, is crucial for activity and
imply that the short cytoplasmic form ofTAR RNA may not
be able to act as a translational activator in vivo. However,
protein synthesis in vivo was stimulated by longer versions of
TAR RNA expressed from a newly constructed vector.
These observations suggest thatTARRNA may prevent DAI
activation in an intact cell when located at the 5' end of viral
mRNAs.
RESULTS
TAR RNA Suppresses the dsRNA-Mediated Inhibition of
Translation. Experiments conducted in vitro with purified
components suggested that TAR RNA might prevent the
inhibition of protein synthesis that results from activation of
DAI by dsRNA (13). To extend these results to a more
physiological setting, we examined the effect of TAR RNA
on globin synthesis in the rabbit reticulocyte lysate transla-
tion system. In this system DAI is ribosome-bound (19) and
probably in a more native state than the purified enzyme used
in the kinase assay. The results of experiments designed to
test the ability of this RNA to inhibit translation and to
prevent translational inhibition by dsRNA are shown in Fig.
1 A and B, respectively.
TAR RNA, purified to remove traces of dsRNA contam-
inants, does not activate DAI (13). To verify that similarly
purified TAR RNA is not inhibitory to cell-free translation,
we preincubated the RNA with the reticulocyte lysate to
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FIG. 1. Effect of wild-type TAR RNA on translation. (A) Neither
TAR RNA nor adenovirus VA RNA inhibits translation in vitro.
Rabbit reticulocyte lysate was preincubated for 15 min at 30°C with
water (lanes 1, 2), reovirus dsRNA (Reo; lanes 3, 4), TAR RNA
(lanes 5-8), or VA RNAi (lanes 9-12). The reaction mixture was
completed by adding globin mRNA (5 gg/ml; Bethesda Research
Laboratories), P5S]methionine [5 mCi/ml (1 Ci = 37 GBq); ICN], 0.4
mM GTP, and other components as specified (20) and incubated for
a further 30 min at 30°C. Translation products were resolved in a 15%
polyacrylamide/SDS gel and visualized by fluorography. No mRNA
was added to the reaction analyzed in lane 1. The globin band is
marked. (B) TAR RNA and VA RNA reverse inhibition by dsRNA.
Reticulocyte lysate was preincubated with reovirus dsRNA alone
(lane 3), or with TARRNA (lanes 4-8), orVA RNA, (lanes 9-13) and
then assayed for its ability to translate globin mRNA. Control
reactions contained no RNA (lane 1) or globin mRNA only (lane 2).
The globin band was quantified by using a Molecular Dynamics
(Sunnyvale, CA) Phosphorlmager, and relative incorporation is
indicated.
permit activation of DAT. The remaining components were
added to complete the translation reaction, and globin syn-
thesis was monitored. Preincubation with reovirus dsRNA
A
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+l
S N
reduced translation to -6% of the control value (Fig. 1A,
compare lanes 3 and 4 with lane 2), presumably by activating
DAI and causing eIF-2a phosphorylation. Preincubation with
TAR RNA had no effect on translation over a range of
concentrations (lanes 5-8), indicating that it fails to activate
DAI. Similarly, VA RNA, also had no effect on translation
(lanes 9-12). These observations are consistent with conclu-
sions drawn from kinase assays by using purified DAI (13,
21).
TAR RNA, like VA RNA (18), blocks the autophospho-
rylation of DAI by dsRNA in a direct kinase assay (13). To
examine this property in the-cell-free translation system, we
tested the ability of TAR RNA to reverse the dsRNA-
mediated inhibition of globin synthesis in the rabbit reticu-
locyte lysate. The lysate was preincubated with reovirus
dsRNA together with TAR RNA or VA RNA; then the
remaining components were added, and translational capa-
bility was assayed by measuring globin synthesis as above.
Inclusion of TAR RNA in the preincubation rescued trans-
lation to -409o of the control level (Fig. 1B, lanes 4-8).
Similar restoration of translational capacity was obtained
with adenovirus VA RNA (lanes 9-13) and with high con-
centrations of dsRNA (>1 Itg/ml), neither of which com-
pletely prevents DAI activation in a kinase assay (data not
shown). It is unclear whether the incompleteness of the
rescue is due to the preincubation protocol or to the existence
of other mechanisms of inhibition by dsRNA besides DAI
activation in the reticulocyte lysate translation system. Nev-
ertheless, these data demonstrate the ability of TAR RNA
and VA RNA to inhibit DAI activation in a cell-free trans-
lation system.
Structral Requirements for TAR RNA Activity. DAI in-
teracts with dsRNA and structured single-stranded RNA
molecules. To define TARRNA features that are required for
its translational role, we made a variety of mutations to
change its structure (Fig. 2A). All ofthese variantTARRNAs
were tested in the translation assay (Fig. 3) and were sub-
jected to secondary-structure analysis (Fig. 4). As illustrated
in Fig. 4A, the S1 and BS mutants are deleted in the apical
loop and at the top of the stem; mutants 3R (9) and NF have
a substitution and an insertion in the stem region, respec-
tively; the Afl and Nhe truncations shorten the RNA to 68 and
48 nt, respectively; and in RATRNA the sequence of nt 3-57
is reversed, whereas that of nt 58-82 is present in the normal
orientation.
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FIG. 2. TAR expression constructs. (A) T7 expression plasmids based on pEM-7 were used to transcribe TAR RNA in vitro (13). RAT
construct contains nt 3-57 of TAR in reverse orientation. Transcription was run off at the HindIII site (H) at +82 of the TAR sequence or at
the Afi I(A) or Nhe I(N) sites. Restriction sites used to make mutations are also marked (B, Bgi TT; S, Sac I). (B) pVA (Lower) contains the
adenovirus 2 VA RNA, gene (22) cloned into pUC119. In the pVA-TAR (Upper), TAR sequences are substituted for a region in the 3' half of
the VA RNA, gene (Lower). Marked are the A box and B box of the VA RNA promoter, the termination sequence MT'), and the regions encoding
the apical stem (ASI and AS2) and central domain (CD) of VA RNA.
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FIG. 3. Rescue of translational inhibition by TAR RNA mutants.
Rabbit reticulocyte lysate was preincubated with reovirus dsRNA
alone (lane 3) or with wild-type (wt) TAR RNA (lanes 4, 5), mutant
TAR RNAs (lanes 6-15, 18, 19), or VA RNAI (lanes 16,17) and then
tested for its capability to translate globin mRNA. Control reactions
contained no RNA (lane 1) or globin mRNA only (lane 2). Globin
synthesis was analyzed by gel electrophoresis (A) and quantified (B).
Alone, none of the RNAs inhibited protein synthesis,
demonstrating that they were free of dsRNA contamination
(data not shown). In the presence ofdsRNA, only mutants S1
and BS were able to rescue translation. They were -60% as
active as wild-type TAR RNA, whereas the remaining mu-
tants, NF, 3R, Afl, Nhe, and RAT, were essentially inactive
(Fig. 3). The results suggested that the stem and terminal
stem-loop structures are essential for DAI interaction,
whereas the apical loop is dispensable. The ineffectiveness of
the RAT RNA suggested that the sequence of the stem might
also be important because this RNA was expected to form a
structure that is the mirror-image of the TAR stem-loop.
Before drawing these conclusions, however, it was necessary
to examine the structures ofthe variantRNAs experimentally
because it is difficult to predict RNA secondary structures
from primary sequence.
To this end we used the technique of nuclease-sensitivity
analysis. The mutantTAR RNAs were probed with a battery
of structure-sensitive nucleases, and the cleavage sites were
determined. Secondary-structure models were derived by
use of a computer program that calculates the most stable
structure based on thermodynamic parameters (23), modified
to incorporate the empirical data defining unpaired nucleo-
tides. The model for wild-type TAR RNA built using this
procedure closely resembles the structure predicted from
sequence alone (24, 25), except that the bulge contains 4 nt
instead of 3 nt, in agreement with chemical-modification data
(26). For the mutant RNAs, however, the discrepancies were
wider because the stability ofshort duplexes was exaggerated
in the absence of empirical data.
The two functional mutants, S1 and BS, formed simple
stem-loops. They retained a substantial part of the wild-type
stem, 20 and 14 base pairs (bp), respectively. In both cases
the deletion caused the formation of a larger loop differing in
sequence from that in wild-type TAR RNA. The 3' terminal
stem-loop structure was retained in mutant S1, but in mutant
BS this sequence was essentially single stranded, suggesting
that this structure is influenced by tertiary interactions with
the rest of the molecule. We infer that a stem structure is
important for function and that 14 bp is sufficient. The
sequence of the apical loop is not critical, and neither the
bulge nor the 3' terminal stem-loop is necessary for function.
The stem mutants 3R and NF exhibited disrupted stems, as
expected, but maintained the wild-type apical loop. Mutant
NF retained the wild-type 3' terminal stem-loop structure,
whereas mutant 3R adopted a different structure, again
consistent with an interaction of this region with the rest of
the molecule. These mutants were inactive (Fig. 3), consis-
tent with the deduction that the stem is important for the DAI
inhibition property and that the bulge-loop at the top of the
stem and the 3' terminal stem-oop structure are dispensable
for this function.
The two truncations, Afl and Nhe, were also inactive. Nhe
is essentially single-stranded, which accounts for its behav-
ior. Afl resembles wild-type TAR RNA, except that the 3'
terminal stem-loop structure is amputated and the RNA
exhibits increased sensitivity to single-strand specific nu-
cleases indicative of structural instability in the stem region.
It is not clear whether this instability or the foreshortening of
the 3' tail is responsible for the loss of function, but with the
caveat that in vivo conditions might be different, it appears
that TAR transcripts of the size seen in transfected cells are
unable to block DAI activation.
As a result ofthe reversal ofthe sequence between nt 3 and
57 in RAT RNA, the stem, bulge, and loop structure was
expected to remain intact but in an opposite orientation.
Unexpectedly this RNA displayed a very open structure,
lacking any duplex longer than 4 bp, although the 3' terminal
stem-loop structure of the molecule retained the wild-type
structure. The inactivity ofRATRNA in the translation assay
(Fig. 3) is again consistent with the inference that inhibition
of DAI activation requires the TAR stem structure.
TARContg RNA S Wmulates Expen from a Trans-
fected 1s. These results confirmed that purified TAR
RNA can prevent activation of DAI by dsRNA in vitro in a
reticulocyte lysate translation assay as well as in a kinase
assay and identified the structural element required. To
determine whether the same response is obtained in vivo and
without RNA purification, we used a transient expression
assay developed to study the function of VA RNA (27-30).
Transfection of the plasmid p8CAT, containing the chloram-
phenicol acetyltransferase (CAT) gene under the direction of
the mouse frglobin promoter (28) into 293 cells, leads to
activation of DAI and eIF-2 phosphorylation (27). The re-
sultant poor expression of CAT is greatly stimulated by
cotransfection of a plasmid producing the VA RNA that
blocks activation of DAI (27, 28).
To express TAR RNA in vivo, we constructed the pVA-
TAR plasmid, in which TAR is placed downstream of the
strong VA RNA, gene promoter (Fig. 2B). Because this RNA
polymerase III promoter is intragenic, the transcribed RNA
is chimeric: VA-TAR RNA is m170 nt long, containing the
TAR sequence (-3 to +82) flanked by 68 nt of VA RNA
sequence on its 5' side and 9 nt on its 3' end. The residual
adenovirus sequences lack both the VA RNA features re-
quired for blocking DAI activation, the central domain and
the apical stem (Fig. 2B). When examined by nuclease-
sensitivity analysis, the regions derived from VA RNA were
Biochemistry: Gunnery et aL
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FiG. 4. Structure of TAR RNA mutants. (A) Locations of TAR mutations are indicated on wild-type (WT) TAR RNA structure. (B)
Secondary structures of wild-type and mutant TAR RNAs were determined by the nuclease-sensitivity method (22). 5'-End-labeled RNA was
partially digested with RNase T1, U2, Bacillus cereus, or T2 (cleaving single-stranded RNA at guanine, adenine, pyrimidines, or any base,
respectively), or by cobra venom RNase VI (specific for duplex regions or stacked nucleotides), and analyzed in denaturingpolyacrylamide gels.
Solid arrowheads indicate positions of single-strand specific cuts; open arrowheads indicate nuclease V1 cuts. Size of the arrowhead denotes
cleavage intensity.
unstructured, as evidenced by frequent single-stranded cuts
(Fig. SC). However, the TAR RNA structure in VA-TAR
was essentially identical to that in free TAR RNA. Thus, the
main structure observed in the molecule was the stem and
loop structure ofTAR RNA together with a small 3' terminal
stem-loop.
Cotransfection of pVA-TAR with the p(3CAT reporter
plasmid resulted in an 8-fold stimulation of CAT enzyme
activity (Fig. 5A). In several experiments, the stimulation
ranged from 3- to 9-fold. In a parallel assay VA RNA
stimulated by 34-fold (range 6- to 34-fold). RNA blot analysis
showed that VA RNA accumulated three to five times the
level of VA-TAR RNA (Fig. SB), which presumably ac-
counts, at least in part, for its lesser ability to stimulate
expression of the reporter plasmid.
DISCUSSION
The Tat protein and TAR element exert a profound effect on
HIV-1 gene expression, and evidence has been adduced for
actions at several levels including translation. Here we have
addressed the interaction between the TAR transcript and the
cellular protein kinase DAI, a key component of the cellular
antiviral defense mechanism triggered by interferon. Based
on studies in model systems, both positive and negative
actions have been reported. Initial work suggested that TAR
RNA activates DAI in vitro, thereby blocking viral gene
expression (10-12, 14). To obtain synthesis of viral proteins,
it was proposed that the inhibitory effect of TAR RNA is
overcome either directly (12) or indirectly (35-37) by Tat. By
contrast, our earlier work indicated that TAR RNA purified
to remove dsRNA contaminants acts as a positive effector,
preventing the activation of DAI by dsRNA (13). Like small
structured RNAs encoded by other viruses (18), this HIV-1
RNA would forestall the inhibition of protein synthesis
initiation that limits translation and viral multiplication. The
present data demonstrate that TAR RNA can prevent the
inhibition of protein synthesis both in vivo and in vitro and
argue strongly that this ability to block DAI activation is a
property of the enzyme and RNA in their native states.
These findings establish the potential of TAR RNA to
counteract the interferon-induced defense mechanism in
vivo, but further information is required to show that it fulfills
this role in the infected cell. As pointed out (13), the structure
of TAR RNA is compatible with its ability to block DAI
activation by dsRNA but not to activate DAI on its own.
Activation requires a perfectly matched RNA duplex of at
least 30 bp, not present in TAR RNA, whereas shorter duplex
regions such as those in TAR RNA can bind to the enzyme
and prevent its activation (38, 39). Analysis of deletion
mutants of TAR RNA led to the conclusion that a duplex of
14 bp is necessary for the DAI-inhibitory function of TAR
RNA, consistent with the observation that the stem region of
TAR RNA is required for DAI binding (14). However, the
inactivity of the TAR.Afl truncation suggests that this length
of duplex may not be sufficient for DAI inhibition. Although
the presence of the 3' stem and loop structure seen in the
82-nt-long TAR RNA does not correlate with function, its
removal results in loss of function, suggesting that a single-
stranded tail of >8 nt is required. Taken at face value, this
observation would militate against the hypothesis that the 58-
to 66-nt TAR transcripts found in vivo (8) play a role in
blocking DAI activation in the cell. Moreover, it is doubtful
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FIG. 5. Stimulation of gene expression in vivo. (A) CAT enzyme activity in lysates of human 293 cells (31) transfected with carrier DNA
only (lanes 1, 2), 3 ug ofpCAT plasmid alone (lanes 3, 4), or with S pg ofpVA (lanes 5, 6), or 10 pig ofpVA-TAR (lanes 7, 8). Salmon sperm
DNA (Pharmacia) was added as a carrier to a total of 13 pg per plate. Cells were harvested at 48-hr posttransfection, and CAT assays (32) were
conducted with two different amounts of lysate. (B) RNA blot (33) of RNA from transfected cells probed with an RNA complementary to the
5' end of VA RNA transcribed from p5'VA (34) cut at Xba I. Cells were transfected with salmon sperm DNA only (lane 1), 3 pg of pCAT
alone (lane 2), or with 5 jg of pVA (lane 3), or 10 ,ug of pVA-TAR (lane 4). (C) Secondary-structure model for VA-TAR RNA.
whether the short TAR transcripts accumulate in the infected
cell to a sufficiently high concentration to block DAI activa-
tion. On the other hand, because DAI activation can be
controlled at the local level (40-42), the possibility remains
open that the TAR structure located at the 5' end of full-
length mRNAs protects HIV-1 protein synthesis against DAI
activation, giving these viral mRNAs a selective advantage
over cellular mRNA when dsRNA is present. The location of
the TAR structure on each viral RNA would position it
ideally for such a cis-acting translational role.
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